Difference between revisions of "Siltuximab (Sylvant)"
(FDA approval) |
m |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Castleman’s disease]] | *[[Castleman’s disease]] | ||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 14: | Line 13: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *4/23/2014: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394522.htm FDA approved] "for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative." | + | *4/23/2014: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394522.htm FDA approved] "for the treatment of patients with [[Castleman’s disease | multicentric Castleman’s disease (MCD)]] who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative." |
==Also known as== | ==Also known as== | ||
| Line 27: | Line 26: | ||
[[Category:IL-6 inhibitors]] | [[Category:IL-6 inhibitors]] | ||
[[Category:Castleman’s disease medications]] | [[Category:Castleman’s disease medications]] | ||
| + | |||
[[Category:Drugs FDA approved in 2014]] | [[Category:Drugs FDA approved in 2014]] | ||
Revision as of 16:46, 12 November 2014
General information
Class/mechanism: Human-mouse chimeric monoclonal antibody which binds interleukin-6 (IL-6). Siltuximab prevents IL-6 from binding to soluble and membrane-bound IL-6 receptors. Blocking IL-6 activity interferes with its processes such immunoglobulin secretion. Systemic manifestations in patients with multicentric Castleman’s disease (MCD) has been associated with overproduction of IL-6.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 4/23/2014: FDA approved "for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative."
Also known as
CNTO 328.